tetano
Editor, Senior Moderator
Thromb Res
. 2022 Jul 5;216:120-124.
doi: 10.1016/j.thromres.2022.06.014. Online ahead of print.
Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
Rebecca Müller[SUP] 1 [/SUP], Gabi Rink[SUP] 1 [/SUP], Günalp Uzun[SUP] 2 [/SUP], Tamam Bakchoul[SUP] 3 [/SUP], Patrick Wuchter[SUP] 1 [/SUP], Harald Klüter[SUP] 1 [/SUP], Peter Bugert[SUP] 4 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19.
Methods: 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43-378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21-74 days and the third (T3) donation after additional 22-78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA.
Results: In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3.
Conclusion: Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
Keywords: CD62P; COVID-19; Plasma marker; Platelet function; SARS-CoV-2 infection; Soluble P-selectin.
. 2022 Jul 5;216:120-124.
doi: 10.1016/j.thromres.2022.06.014. Online ahead of print.
Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
Rebecca Müller[SUP] 1 [/SUP], Gabi Rink[SUP] 1 [/SUP], Günalp Uzun[SUP] 2 [/SUP], Tamam Bakchoul[SUP] 3 [/SUP], Patrick Wuchter[SUP] 1 [/SUP], Harald Klüter[SUP] 1 [/SUP], Peter Bugert[SUP] 4 [/SUP]
Affiliations
- PMID: 35810548
- DOI: 10.1016/j.thromres.2022.06.014
Abstract
Background: The coronavirus disease-2019 (COVID-19) is a systemic disease with severe implications on the vascular and coagulation system. A procoagulant platelet phenotype has been reported at least in the acute disease phase. Soluble P-selectin (sP-sel) in the plasma is a surrogate biomarker of platelet activation. Increased plasma levels of sP-sel have been reported in hospitalized COVID-19 patients associated with disease severity. Here, we evaluated in a longitudinal study the sP-sel plasma concentration in blood donors who previously suffered from moderate COVID-19.
Methods: 154 COVID-19 convalescent and 111 non-infected control donors were recruited for plasma donation and for participation in the CORE research trial. First donation (T1) was performed 43-378 days after COVID-19 diagnosis. From most of the donors the second (T2) plasma donation including blood sampling was obtained after a time period of 21-74 days and the third (T3) donation after additional 22-78 days. Baseline characteristics including COVID-19 symptoms of the donors were recorded based on a questionnaire. Platelet function was measured at T1 by flow cytometry and light transmission aggregometry in a representative subgroup of 25 COVID-19 convalescent and 28 control donors. The sP-sel plasma concentration was determined in a total of 704 samples by using a commercial ELISA.
Results: In vitro platelet function was comparable in COVID-19 convalescent and control donors at T1. Plasma samples from COVID-19 convalescent donors revealed a significantly higher sP-sel level compared to controls at T1 (1.05 ± 0.42 ng/mL vs. 0.81 ± 0.30 ng/mL; p < 0.0001) and T2 (0.96 ± 0.39 ng/mL vs. 0.83 ± 0.38 ng/mL; p = 0.0098). At T3 the sP-sel plasma level was comparable in both study groups. Most of the COVID-19 convalescent donors showed a continuous decrease of sP-sel from T1 to T3.
Conclusion: Increased sP-sel plasma concentration as a marker for platelet or endothelial activation could be demonstrated even weeks after moderate COVID-19, whereas, in vitro platelet function was comparable with non-infected controls. We conclude that COVID-19 and additional individual factors could lead to an increase of the sP-sel plasma level.
Keywords: CD62P; COVID-19; Plasma marker; Platelet function; SARS-CoV-2 infection; Soluble P-selectin.